Portland State University

PDXScholar
University Honors Theses

University Honors College

Summer 2020

Differential Effects of Buprenorphine/Naloxone Vs.
Methadone on Quality of Life Over Time: A Subset of
The BRAVO Study (Buprenorphine to Improve HIV
Care Engagement and Outcomes: A Randomized
Trial)
Ali Mirzazadeh Javaheri
Portland State University

Follow this and additional works at: https://pdxscholar.library.pdx.edu/honorstheses
Part of the Community Health and Preventive Medicine Commons, and the Other Medical Sciences
Commons

Let us know how access to this document benefits you.
Recommended Citation
Mirzazadeh Javaheri, Ali, "Differential Effects of Buprenorphine/Naloxone Vs. Methadone on Quality of
Life Over Time: A Subset of The BRAVO Study (Buprenorphine to Improve HIV Care Engagement and
Outcomes: A Randomized Trial)" (2020). University Honors Theses. Paper 953.
https://doi.org/10.15760/honors.976

This Thesis is brought to you for free and open access. It has been accepted for inclusion in University Honors
Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more
accessible: pdxscholar@pdx.edu.

Differential Effects of Buprenorphine/Naloxone Vs. Methadone on Quality of Life
Over Time: A Subset of The BRAVO Study (Buprenorphine to Improve HIV Care
Engagement and Outcomes: A Randomized Trial)

by
Ali Mirzazadeh Javaheri

An undergraduate honors thesis submitted in partial fulﬁllment of the
requirements for the degree of
Bachelor of Science
in
University Honors
and
Science

Thesis Adviser
Dr. Todd Korthuis, MD, MPH

Portland State University
2020

- Abstract
Health-related Quality of Life (QoL) is generally poorer in individuals with opioid use disorder
(OUD) in comparison with those suffering from other chronic diseases.11 Little is known about
the difference each buprenorphine/naloxone (BUP/NX) or methadone maintenance therapy
(MMT) may make in the QoL for the HIV-infected people with OUD who are new to HIV care.
The objective of this study is to evaluate the difference in the impact that BUP/NX and MMT
treatment delivery models make on the QoL of the HIV-infected participants with OUD in
Vietnam.
This study was a subset of the BRAVO study, buprenorphine to improve HIV care engagement
and outcomes: a randomized trial. This study analyzed the QoL data from 254 participants (121
participants belonging to the BUP/NX group), excluding 30 due to lack of follow-up
assessments, based on EUROQOL’s EQ-5D instrument standards.
Examination of the 5-level Likert scale of the five dimensions of mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression over 12 months suggests both treatment
delivery models tend to improve QoL for the patients of such cohort, but not in all dimensions.
Self-care and activity level were two of the dimensions which did not seem affected by either of
the treatment delivery models. And the BUP/NX randomized group demonstrated more
favorable improvements in the mobility and pain dimensions while anxiety levels were improved
almost equally in both groups.
Keywords: Quality of life, health related quality of life, buprenorphine, naloxone, methadone,
HIV, Vietnam

- Background
Individuals with opioid use disorder (OUD) are at a higher risk for transmission of viral
infections like human immunodeficiency virus (HIV), HBV, and HCV due to both unsafe sexual
activity and sharing injection equipment such as needles.1 It has also been documented that this
population is more prone to overdose.9 In Vietnam, the number of people who use drugs
(PWUD) increased by 70% between 2000 and 2004.2 By 2006, the HIV prevalence rate among
PWUD increased to 70-85% in several areas.3 The opioid crisis and its linkage to HIV and other
viral infections continue. Moreover, injection drug use (IDU) adversely impacts engagement
across the continuum of HIV care: being diagnosed with HIV promptly, linking to HIV care,
receiving, and adhering to antiretroviral therapy (ART), staying in HIV care, and achieving HIV
viral suppression.
Methadone maintenance therapy (MMT) can both decrease the risk of transmitting HIV and
support access, utilization, and outcomes of HIV-related services in the case of injection driven
HIV epidemics.4 “MMT is a long-term and slow-onset substitution therapy, which needs
complete medication adherence to achieve optimal outcomes … and it has been well documented
that patients’ adherence to MMT was not optimal and the retention rate was just 40% [between
2015 and 2018 in Vietnam and few other countries]”.5 Although MMT is actively implemented
in Vietnam, only 65.6% of individuals under treatment did not have optimal adherence to
MMT.5,6

Another course of action for opioid maintenance therapy is implementing use of
buprenorphine/naloxone (BUP/NX). BUP/NX, a partial opioid agonist, is a safer and less risky
treatment in comparison to methadone, a full opioid agonist, which requires close monitoring.7
BUP/NX reduces overdose risk and deaths as MMT does. It, however, has less potential for
abuse, and causes less analgesia and euphoria symptoms compared with Methadone.9 Due to
BUP/NX’s “ceiling effect”, respiratory suppression will not increase after reaching a certain
threshold.10 However, despite the positive qualities of BUP/NX, patients on BUP/NX are less
likely to be retained in treatment compared to those treated with MMT.
Nonetheless, training HIV providers to manage OUD with buprenorphine/naloxone (BUP/NX)
during HIV clinic visits has the potential to expand access to opioid dependence treatment while
increasing engagement in HIV care.
Health-related Quality of Life (QoL) is generally poorer in individuals with OUD in comparison
with those suffering from other chronic diseases.11 Little is known about the difference each
BUP/NX or MMT may make in the QoL for the HIV-infected people with OUD who are new to
HIV care. The objective of this study is to evaluate the difference in the impact that BUP/NX and
MMT treatment delivery models make on the QoL of the HIV-infected participants with OUD.
The results of this study are to help researchers and clinicians assess relative QoL related
differences in each treatment delivery method.

- Methods
a. Study design and setting
This study reports the effect of BUP/NX treatment model vs. MMT treatment model on quality
of life over time for individuals participating in the Buprenorphine to Improve HIV Care
Engagement and Outcomes (BRAVO) Randomized Trial (ClinicalTrials.govNCT01936857).
The BRAVO study enrolled HIV infected individuals with moderate to severe OUD were
randomized to receive HIV clinic based BUP/NX versus referral for MMT for treatment of OUD
at six Vietnamese HIV clinics from 2015 to 2019.
The study sites were four HIV clinics in Hanoi, one in Thanh Hoa, and one in Bac Giang; all of
which are associated with MMT and HIV testing and counselling centers. Additional outreach
recruitment, non-medication-related study procedures and linkage of participants to participating
HIV clinic sites for clinical management were carried out by the research coordinating center at
Hanoi Medical University (HMU).
This study was conducted in partnership with HMU, the Providence AIDS Control (PAC)
authorities of Hanoi, Thanh Hoa, and Bac Giang, the Vietnam National Institute of Mental
Health, and Oregon Health and Science University (OHSU). n+1
b. Participants
HIV positive participants who had a current moderate to severe DSM-5 OUD diagnosis, tested
positive for opioids through urine drug screening were included in the study. These participants

had interest in receiving treatment for opioid dependence and were at or above the age of 18. If
female, these participants were willing to practice effective methods of birth control as the study
inclusion criteria suggested.
Participants were excluded if they had a known hypersensitivity to buprenorphine or naloxone,
AST & ALT > 5x the upper limit, serious medical or psychiatric illness in past 30 day (e.g.
opportunistic infection, psychosis) that precludes safe participation in the opinion of study
physician, and received MMT within 30 days of consent. Exclusion criteria also included those
who were pregnant or breastfeeding. In addition, known vulnerable populations (children,
pregnant women, decisionally-impaired adults, and prisoners) were excluded.
c. Measures
The QoL data was collected and analyzed based on EUROQOL’s EQ-5D instrument standards, a
preference-based measure of health status that is used in clinical trials and population studies. In
this standard method of measurement, five dimensions of mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression are examined to measure health-related quality of life.8
Each dimension is a 5-level Likert scale; the values are non-arithmetic. Each value from 1-5,
respectively represents, no problems, slight problems, moderate problems, severe problems and
unable to.
The number of enrolled participants with QoL data was 284; 30 of whom were excluded in the
data analysis due to lack of follow-up assessments. The remaining randomized sample included
121 participants belonging to the BUP/NX group and 133 participants belonging to the MMT
referral group.
Participants reported QoL during quarterly survey assessments through 12 months follow-up (i.e.
5 possible responses per participant across time).
d. Data analysis
Data analysis and visualization were done through the Microsoft Excel and Tableau software.
Five graphs were made for each QoL dimension for both treatment models.

-

Data

Figure 1. EQ-5D Anxiety dimension by treatment group. Group 1 (BUP/NX) is displayed on the
left along with group 2 (MMT) on the right. Slight improvement in Anxiety levels towards the
middle of the study followed by a decreasing value towards the end of the study is observed in
BUP/NX group. The MMT group shows steady, yet slight, improvement in anxiety. The level of
difference in improvement towards the end of study is small.

Figure 2. EQ-5D Mobility dimension by treatment group. Group 1 (BUP/NX) is displayed on the
left along with group 2 (MMT) on the right. Slight and quiet steady improvement in mobility
levels is observed in BUP/NX group, through the course of study. While MMT group shows
slight improvement towards the middle of study followed by a diminished level almost equal to
the beginning values. The results suggest better mobility in the BUP/NX group by the end of
study.

Figure 3. EQ-5D Selfcare dimension by treatment group. Group 1 (BUP/NX) is displayed on the
left along with group 2 (MMT) on the right. Very minimal level of improvement is shown in
both groups, in the same consistent pattern.

Figure 4. EQ-5D Pain dimension by treatment group. Group 1 (BUP/NX) is displayed on the
left along with group 2 (MMT) on the right. Minimal improvement is observed in a quiet
consistent manner in the BUP/NX group. The MMT group shows most improvement in the
third and ninth months of follow up with a regression to levels close to baseline by the end of
the study. The BUP/NX group suggests slightly more favorable results by the end of the
study.

Figure 5. EQ-5D Activities dimension by treatment group. Group 1 (BUP/NX) is displayed
on the left along with group 2 (MMT) on the right. There is little change in both group with
favorable values from the beginning to the end of the study.

-

Discussion

QoL for HIV infected individuals with OUD is known to be severely compromised; both
BUP/NX and MMT treatment delivery models have been found in improving QoL.12,13,18
This study suggests both BUP/NX and MMT treatment delivery models tend to generally improve
QoL for the patients of such cohort, but not in all five EQ-5D dimensions. Moreover, not all these
improvements seem to be consistent over time. Self-care and activity level were two of the
dimensions which did not seem affected by either of the treatment delivery models. A longitudinal
study assessing changes in drug use patterns and QoL among a similar population (HIV-infected
drug users in Vietnam) partially confirms this outcome as it showed MMT treatment delivery
model mostly improved QoL in the psychological dimensions.19 Anxiety, mobility, and pain
dimensions showed promising results regarding both treatment delivery models.
The MMT group showed steady, yet slight, improvements on anxiety levels. Regarding mobility,
this group showed slight improvement towards the middle of the study followed by a regression
to levels almost equal to the beginning values. Pain levels in this group were mostly improved in
the third and ninth months of follow up with, yet another, regression to levels close to baseline by
the end of the study.
The BUP/NX group showed slight improvement in anxiety levels towards the middle of the study
followed by a decrease towards the last quarter of the study. Mobility and pain levels in this group
improved slightly in a steady manner. Overall, the BUP/NX randomized group demonstrated more
favorable improvements in the mobility and pain dimensions while anxiety levels were improved
almost equally in both groups. Other studies confirm the effectiveness of BUP/NX in improvement
in the pain dimensions by showing “improvements in vitality, social functioning, role physical and
emotional, and mental health.”25
The modest improvements in QoL and the diminishing benefits in both treatment models have
been shown in another study.14 It is recommended that the effectiveness of these treatments has
the potential to improve QoL through reduction in drug use and withdrawal symptoms, decreased
drug-seeking behavior and increased access to psychosocial and pharmacological treatment for comorbid conditions.”15,16 As suggested by Volkow and Montaner, there is a possible threshold level
to these modes of treatment which is contributed to by “co-occurring mental health conditions,
infectious diseases such as HIV and HCV, [and] other chronic medical conditions” in individuals
with OUD.17
In other studies, although rapid improvement in QoL during the first quarter after applying MMT
treatment model was observed; it was decelerated beyond the first three months.18 Furthermore,
higher dosage of methadone and longer retention were predicted to be associated with higher
QoL.18 However, another study shows that despite the effectiveness of MMT in “reducing heroin
use, injecting practices and crime, and in improving in social functioning and physical symptoms
… the improvement in [QoL] was not significantly greater as the duration of treatment
increased.”20 For further confirmation, Ponizovsky znc Grinshpoon demonstrated that despite the
almost immediate positive results in QoL using an MMT treatment delivery model, the results are
short term, yet reach a comparable quality of life quicker than BUP/NX treatment delivery

model.21 Studies seem mixed up on the time span over which the improvement is observed as
another study has shown improvement over two to four quarters of MMT.22
In comparison with MMT, BUP/NX is thought to have less severe side effects such as less
respiratory depression and euphoria while remaining nearly equally effective in decreasing opioid
use and is proven to improve QoL in conjunction with psychological counseling.23-26
One of the limitations of this study is not being able to control for opioid use after beginning
treatment. Opioid use in the long term alters the brain circuitry.27 The potential for return to use
may explain for multiple cases of loss of initial improvement observed earlier in this study.
Furthermore, the study did not consider the role of BUP/NX’s “ceiling effect” in the participants’
response to the self-reports evaluating the QoL in each treatment model. The decrease in the level
of experienced euphoria in the BUP/NX group might have affected their perception of their health
related QoL. The data does not generalize to all the patients receiving these forms of treatments.
The plateauing trend noted in many of the figures may be due to the QoL of the participants
reaching the same level as that of the region’s population. Thus, analyses of the EQ-VAS data and
normalizing it to the main population’s data would provide further insight and help with ruling out
some of the limitations. The future studies intend to address these limitations to provide better
insight and source for making better judgment regarding the subject matter.
-

Conclusion

The objective of this study was to evaluate the difference in the impact that BUP/NX and MMT
treatment delivery models make on the QoL of the HIV-infected participants with OUD in
Vietnam. Both treatment delivery models demonstrated the tendency to improve QoL for the
HIV-infected individual with OUD living in Vietnam, but not in all dimensions. Self-care and
activity level were two of the dimensions which did not seem affected by either of the treatment
delivery models. And the BUP/NX randomized group demonstrated more favorable
improvements in the mobility and pain dimensions while anxiety levels were improved almost
equally in both groups.
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